Retatrutide Research Guide: The Triple Agonist Explained

Retatrutide is the most requested research peptide in Australia right now, and for good reason: it is the first triple agonist — GLP-1, GIP and glucagon receptors — to produce headline phase-2 data, and it remains investigational, which places it squarely in research territory.

Mechanism in brief

Where semaglutide activates one incretin receptor and tirzepatide two, retatrutide adds the glucagon receptor. In published models the glucagon component is associated with energy-expenditure signalling — a different axis from the intake-side pathways of GLP-1/GIP. Three receptors, three overlapping cascades: a rich system for signalling research.

The published record

Phase-2 results reported in 2023 drew unprecedented attention to the molecule, and follow-on publications continue. For researchers this matters practically: an investigational compound with an active literature means fresh comparison data for receptor and signalling work.

Handling notes

Retatrutide ships lyophilised; store at -20°C, reconstitute with bacteriostatic water (our calculator handles concentrations), and hold solutions at 2-8°C. As a long modified sequence it demands tight synthesis quality — our vials are HPLC-verified ≥99% with MS identity confirmation on the batch COA.

Sourcing in Australia

We stock retatrutide in 5mg, 10mg and 15mg vials, dispatched express from within Australia with batch documentation available on request — see the product page for current pricing, or the Complete Research Bundle to pair it with GHK-Cu and a starter kit.

Volume buyers and peptide businesses can source wholesale stock, tested in Australia, through our trade and white-label program.

All compounds discussed are for in-vitro laboratory research only and are not for human or veterinary use.